858 Therapeutics

Founded by a veteran team with a successful track record in pharma and biotech drug discovery, 858 Therapeutics is a biotechnology company focused on developing small molecule drugs targeting novel therapeutic areas. Their core mission is to innovate treatments in oncology, neuroscience, and cardiovascular disease by focusing on synthetic lethality, innate immunity, and RNA modulation. The company aims to address unmet medical needs through cutting-edge drug discovery and development.

Notable affiliated individuals include experienced leaders from the pharmaceutical and biotech industries. 858 Therapeutics has garnered attention for its pioneering approach to targeting RNA regulation and the immune response in cancer therapy. Their key achievements include advancing a robust pipeline of drug candidates and securing strategic partnerships. The overall impact of 858 Therapeutics lies in its potential to transform treatment paradigms for serious diseases, offering new hope to patients worldwide.